have confirmed abnormally low serum brain-derived neurotrophic factor (BDNF) concentrations in depressed patients and normalization of this by antidepressant treatment. These findings are believed to reflect peripheral manifestations of the neurotrophin hypothesis, which states that depression is secondary to an altered expression of BDNF in the brain. Since the publication of these meta-analyses, the field has seen a huge increase in studies on these topics. This motivated us to update the evidence on the aforementioned associations and, in addition, to compile the data on serum BDNF concentrations in relation to the symptom severity of depression. Using a manifold of data as compared with earlier meta-analyses, we find low serum BDNF concentrations in 2384 antidepressant-free depressed patients relative to 2982 healthy controls and to 1249 antidepressant-treated depressed patients (Cohen's d ¼ À 0.71 and À 0.56, P-values o0.0000001). When publication bias is accounted for, these effect-sizes become substantially smaller (d ¼ À 0.47 and À 0.34, respectively, P-valueso0.0001). We detect between-study heterogeneity in outcomes for which only year of publication and sample size are significant moderators, with more recent papers and larger samples sizes in general being associated with smaller between-group differences. Finally, the aggregated data negate consistent associations between serum BDNF concentrations and the symptom severity of depression. Our findings corroborate the claim that altered serum BDNF concentrations are peripheral manifestations of depression. However, here we highlight that the evidence for this claim is slimmer as was initially thought and amidst a lot of noise.
INTRODUCTION
The neurotrophin hypothesis, originally formulated in 1997 by Duman, Heninger and Nestler, characterizes major depressive disorder as being secondary to aberrant neurogenesis in brain regions that regulate emotion and memory. 1 According to this hypothesis, aberrant neurogenesis is brought about by a (stress induced) lower expression of brain-derived neurotrophic factor (BDNF). In addition, the neurotrophin hypothesis predicts that antidepressants are efficacious because they increase BDNF expression and herewith resolve aberrant neuronal plasticity. 2, 3 A large pre-clinical literature, allowing for mechanistic insights, fits very well with these predictions. Taliaz et al., 4 for instance, showed in rats that a reduction of BDNF in the dentate gyrus impairs neurogenesis and induces depressive-like behavior. Human postmortem studies have indicated similar alternations in the brains of persons who were depressed at the time of dying. 5 Further support for abnormalities in BDNF expression in depressed patients comes from clinical studies. Karege et al. 6 as the first found serum BDNF concentrations to be low in depressed patients as compared with healthy controls and lowest in persons with the highest levels of symptom severity. Shimizu et al. 7 were the first to show an increase in serum BDNF concentrations in the course of antidepressant treatment. 7 These findings generated a buzz of research activity and in 2008-2010 the clinical data were summarized in three metaanalyses. [8] [9] [10] These meta-analyses, basically including the same 11 studies (NB968) confirmed the finding of low serum BDNF concentrations in untreated depressed patients (effect-size (Cohen's d)B À 1) and normalization of this by antidepressant treatment (dB1) while suggesting that these associations were not hampered by between-study heterogeneity or publication bias. Accordingly, the conclusion was: BDNF may have potential use as biomarker for psychiatric disorders or as a predictor of antidepressant efficacy (page 527). 9 Since then, the field has seen an abundance of new data on these topics. Important is that this new data entail striking variation in outcomes across studies. 11, 12 This, and the abundance of new data, motivated us to update the current state of knowledge by calculating pooled effect-size estimates on differences in serum BDNF concentrations among:
antidepressant-free depressed patients and healthy controls subjects antidepressant-free-and antidepressant-treated depressed patients antidepressant-treated depressed patients and healthy controls subjects.
We chose to focus on serum BDNF concentrations, and not on related parameters such as plasma or whole blood BDNF concentrations, because we wished to avoid an additional source of bias. Besides, in depression research, serum BDNF concentrations are most commonly used.
An additional aim was to compile the data on the putative relation between serum BDNF concentrations and the symptom severity of depression in:
antidepressant-free depressed patients antidepressant-treated depressed patients healthy control subjects. A final aim, made possible by a large amount of studies, was to learn on the potential influence that some relevant moderators might have on the outcomes of our interest.
MATERIALS AND METHODS
We adhered to the guidelines that are recommended by the preferred reporting items for systematic reviews and metaanalyses statement. 13 The literature search, decisions on inclusion, data extraction and quality control were all performed independently by two of the authors (MP or BB and MM).
Search strategy
We searched the PUBMED, Embase and PsychInfo through 1st April 2013 to identify eligible human studies on serum BDNF concentrations in healthy controls, depressed patients or in both. These digital searches were supplemented by backward searches in which the references to the seminal papers of interest were screened 6, 7 and by examining the reference sections of the retrieved papers.
Inclusion criteria
We included peer-reviewed human studies that reported data on serum BDNF concentrations in healthy controls, and antidepressant-free and antidepressant-treated depressed patients. Inclusion was independent of clinical (for example, psychiatric comorbidity) and the methodological characteristics of the sample or study (for example, between-subject design versus within-subject design). Non-empirical studies were excluded, as were studies that were not written in English, Dutch, German or Spanish. Overlapping samples were excluded except for the one that reported on the largest number of subjects.
Data extraction
We extracted, as primary outcomes, mean serum BDNF concentrations and s.d. as a function of diagnostic status and antidepressant use and/or indices on the relation between BDNF concentrations and the symptom severity of depression (for example, Pearson's r). When BDNF concentrations were assessed at multiple time points, we extracted the data recorded at baseline and at the longest follow-up period.
We also extracted data on mean age, gender distribution, depression severity, antidepressant use (subdivided by selective serotonin reuptake inhibitors, tricyclic antidepressants, selective norepinephrine reuptake inhibitors, and noradrenergic and specific serotonergic antidepressants), duration of antidepressant use and the number of subjects in the study. Where records did not provide sufficient information, corresponding authors were contacted and the required data were requested. In those cases, where nonsignificant results were reported in a paper (for example, P40.05) and authors did not reply to our request, we assigned the associations an estimated effect-size of zero.
Quality assessment
We used the Newcastle-Ottawa Scale (NOS) 14, 15 to assess the quality of the included studies. Overall quality score was defined as the frequency of criteria that were met by the particular study. We excluded NOS items 4 and 7 because these are meaningless in the context of the current paper. Mean-quality score of the included studies was 3.18 (s.d. ¼ 0.14). The agreement between the independent raters was excellent (Cohen's kappa ¼ 0.89, s.e. ¼ 0.03).
Statistical analysis All calculations were performed using comprehensive metaanalyses 2.0. 16 Random-effects models were applied to calculate pooled Cohen's d's 17 on between-group differences in serum BDNF concentrations. Pooled correlation coefficients were calculated on the relation between serum BDNF concentrations and the symptom severity of depression. All outcomes were weighted using inverse variance methods. 16 Statistical significance of the pooled effect-sizes was assessed using a confidence interval (CI) of 95%. The I 2 measure was used to quantity the amount of between-study heterogeneity and considered to be high when I
2

450%.
18,19 Statistical significance of heterogeneity was assessed using the Q-statistic.
16
Through meta-regression analyses, the possible moderating effects of between-study differences on outcomes were evaluated. We considered the number of subjects included in the study, year of publication, mean age, symptom severity of depression of the patient sample, gender distribution and the NOS score as potential moderators for all outcomes of interest. The severity rating scales that were used differed between studies. These instruments use different values to quantify severity (for example, refs. Hamilton et al. 20 and Rush et al. 21 ) that do not necessarily equate to each other. Therefore, we used the validated severity categories (that is, none, mild, moderate, severe and very severe) that can be derived from the continuous scores on each of these instruments as potential moderating variable. The moderation analysis on the difference in serum BDNF concentrations between healthy controls and antidepressant-treated depressed patients in addition included variables coding for the class of antidepressant and the duration of treatment. For the meta-analysis on antidepressant-free and antidepressant-treated depressed patients, the set of moderators was extended with a variable coding for change in depression severity over treatment defined as the percentage of improvement on the depression rating scale that was used.
Publication bias was assessed by inspection of funnel plots and the Egger test. 22 The trim-and-fill procedure, a validated manner to estimate an effect-size after bias has been taken into account, 23, 24 was performed in case of publication bias. Power and sample size calculations were performed using G*Power. 25 Stability of our results was evaluated by sensitivity analyses in which each study was excluded from analyses at a time.
RESULTS
Our initial search generated 730 papers of which 55 fulfilled the inclusion criteria for at least one of our meta-analyses. 6, 7, 11, 12, From these papers, we could extract 124 between-group effectsize estimates and 55 correlation coefficients. For details on the search strategy, we refer to the flowchart ( Figure 1 ). Table 1 lists in which meta-analysis the papers were included and provides demographic and clinical characteristics of the included studies. A meta-analysis aggregating 30 associations (n ¼ 1807) on the relation between BDNF concentrations and the symptom severity of depression yielded a statistically significant, negative correlation (r ¼ À 0.19; 95% CI ¼ À 0.28 to À 0.10, Po0.00001) in antidepressant-free depressed patients. There was no evidence for a relation between serum BDNF concentrations and depression severity in antidepressant-treated depressed patients (r ¼ À 0.02; P ¼ 0.36, 20 associations, n ¼ 1820) or in healthy controls (r ¼ À 0.02; P ¼ 0.41, 5 associations, n ¼ 2276). Forest plots are provided as supplement ( Supplementary Figures S4-S6 ).
Meta-analyses
Between-study heterogeneity and moderation analyses A large amount of between-study heterogeneity in outcomes was identified in all meta-analyses that yielded significant outcomes (55%oI 2 o87%, for I 2 -, Q-and P-values we refer to Table 2 ). In a series of meta-regression analyses, we aimed to identify sources of heterogeneity in outcomes. We observed that differences in serum BDNF concentrations among antidepressant-free depressed patients and healthy control subjects could partly be explained by sample size (r ¼ À 0.33, R 2 ¼ 0.11, P ¼ 0.03) and by year of publication (r ¼ À 0.30, R 2 ¼ 0.09, P ¼ 0.04), with larger samples and more recently reported papers in general reporting smaller between-group differences. In the meta-analysis on changes in serum BDNF concentration over the course of antidepressant treatment, we found that a larger decrease in symptom alleviation was accompanied by a larger increase in BDNF concentrations (r ¼ À 0.48, R 2 ¼ 0.22, P ¼ 0.01). Other moderators, including NOS score, were not observed (see Table 3 for all coefficients). Moderation analyses were not performed when between-study heterogeneity was not detected.
Publication bias and power Visual inspection of the funnel plots suggested that there was evidence for publication bias in all meta-analyses that yielded a significant outcome. Egger's tests confirmed this (t-values in the range 2.5-4.2, P-values all o0.05, see Table 2 for exact values).
Trim-and-fill estimations were used to assess the impact of publication bias. The meta-analysis on differences in BDNF concentrations among healthy controls and untreated depressed patients suggested that nine studies had to be imputed to result in a symetric funnel plot. Imputation led to a smaller, yet significant, effect-size (d ¼ À 0.47, 95% CI ¼ À 0.64 to À 0.27, Po0.000001). The pattern of publication bias was similar in the meta-analyses comparing group differences among antidepressant-free and antidepressant-treated subjects, where five (all data) and four studies (within-subjects data) needed to be imputed to yield a symetric funnel plot. Also here, imputation led to smaller effect-size estimates (d ¼ À 0.54 and À 0.34, respectively, P-valueso0.001). Similarly, for the meta-analyses on the continuous association between serum BDNF concentrations and the symptom severity of depression in untreated depressed persons, Figure 1 . Flowchart of the search strategy and results. BDNF: brain-derived neurotrophic factor; HC, healthy controls; MDD, major depressive disorder.
A A total of 192 records reported on the BDNF gene, 193 records were reviews, perspectives, comments or hypotheses, 36 records reported on animal data, 14 records were post-mortem studies, 12 records were in vitro studies and 111 records did not rapport on BDNF.
B In all, 2 records reported overlapping data, 3 records reported on the BDNF gene, 64 records reported on plasma BDNF concentrations, 3 records were reviews and 43 records did not reported on serum BDNF concentrations in illnesses other than depression and did not indicate that depression-related assessments were performed.
C Most of the papers provided input for 41 meta-analytical effect-size. The number of comparisons/associations, therefore, do not add up to 57. This column, Design, indicates whether within-subjects data (W-S), a betweensubjects data (B-S), or a combination of these types of data (both) is used by the study that is indicated in the corresponding row. Note that the numbers in the column n do not add to the numbers as they are given in the column N. This is because the numbers in column n, in some instances, are counted double (for example, before and after antidepressant treatment in longitudinal designs).
Serum BDNF concentrations as peripheral manifestations of depression ML Molendijk et al Figure 2 . Forrest plot for random-effect meta-analysis on differences in serum BDNF concentrations between healthy control subjects and antidepressant-free depressed patients. The sizes of the squares are proportional to sample size. Here, only associations were included that were derived using a within-subjects designs (that is, treatment studies).
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the trim-and-fill estimations suggested that five studies had to be imputed to result in a symetric funnel plot pattern. Herewith, the effect-size estimate (r ¼ À 0.07) was no longer statistically significant. Funnel plots are provided as Supplement (Supplementary Figures S7-S10) .
We calculated the numbers of subjects that are needed to detect differences with a power of 0.80 at an a-level of 0.05 (one-sided). Hereto we used the pooled effect-size estimates that were corrected for publication bias. These calculations suggested that 57 subjects in each group would be necessary to reliably detect differences in serum BDNF concentrations between healthy controls and antidepressant-free depressed subjects. For differences in serum BDNF concentrations among antidepressant-free and antidepressant-treated persons, this number would be 108. Based on this, the majority of the included samples was not sufficiently powered (observed median sample size ¼ 36). Sample-size calculations were not performed for continuous associations between serum BDNF concentrations and the symptom severity of depression because these were not statistically significant.
Sensitivity analyses indicated that none of the study findings was unduly driven by the effect of a particular study.
DISCUSSION
Here we confirm, based on a manifold of data as compared with previous meta-analyses, [8] [9] [10] that serum BDNF concentrations are low in untreated depressed patients and normalized by antidepressant treatment. The moderate-to-large effect-sizes that we rapport on these differences (random-effects metaanalyses, d ¼ À 0.71 and À 0.56, respectively) are similar to the ones that were reported in the seminal studies 6, 7 and in previous meta-analyses. [8] [9] [10] These findings are not new. The novelty of our work, instead is that here we highlight a large amount of unexplained between-study heterogeneity in outcomes, underpowered study designs, publication bias that together may call for a critical interpretation of the claim that altered serum BDNF concentrations are related to the illness major depression.
We find a large amount of between-study heterogeneity in outcomes and none of the theoretically relevant variables that we tested (for example, the symptom severity of depression or gender distribution of the sample) was associated with this.
Obviously, the heterogeneity may have come from betweensample characteristics that were not tested in our study, such as alcohol consumption and smoking, 79 sleep problems, 80 seasonality 81 or exposure to trauma. 82 Given that depression is a heterogeneous illness, 83 heterogeneity in outcomes may also have come from diversity in clinical characteristics of patient samples. The severity of depression, however, did not explain it. Unfortunately, we did not have the opportunity to test many of the other clinical characteristics because most of the included studies did not report on these variables.
We did find an artificial base for the heterogeneity in outcome. First, a large part of the studies included in our meta-analysis was underpowered. Given that a low level of power increases the false versus true-positive ratio, 84 some overly positive findings may have been among the studies that we included, causing heterogeneity in outcomes. Second, we found that sample size and year of publication were significant predictors of betweenstudy heterogeneity, with larger samples and more recently published findings being associated with smaller between-group differences. This points to publication bias; a particular threat to the validity of a meta-analysis. 85 We found evidence for publication bias in funnel plots. 86, 87 Thus, we applied validated trim-and-fill procedures to provide effect-size estimates that can account for this. 23 These yielded attenuated effect-size estimates that were about half as large as those reported in previous metaanalysis [8] [9] [10] and of moderate magnitude at best (that is, d ¼ À 0.47 through À 0.34). The often discussed association between serum BDNF concentrations and the symptom severity of depression, 6 ,65 for which we initially found evidence, even lost its statistical significance after correcting for publication bias and thus likely does not exist. Given that the relevance of a diagnostic biomarker (that is, a variable that is able to distinguish between diagnostic groups) 88 depends on the magnitude of an effect-size (and not on statistical significance per se 88, 89 ) we conclude that serum BDNF concentrations are likely to be of little clinical use (as has been suggested in two earlier, and excellent reviews 90, 91 ). Complicating this even more is that low serum BDNF concentrations have been reported in persons diagnosed with schizophrenia, 92 bipolar disorder, 93 eating disorders 94 and anxiety 95 indicating that serum BDNF concentrations are not specific enough to differentiate among diagnoses. Multiple-assay methods may serve a role as biomarker better, as recently has been shown. 76 Abbreviations: HC, healthy controls; MDD À , antidepressant-free MDD; MDD þ , antidepressant-treated MDD patients; NaSSA, noradrenergic and specific serotonergic antidepressants; NK, not known; SNRI, serotonin-norepinephrine reuptake inhibitors; SSRI, selective serotonin reuptake inhibitors; TCA, tricyclic antidepressants; W-S, within-subjects data only (that is, associations were that were derived using a within-subjects design. Note: Given that there was no evidence for between-study heterogeneity, moderation analysis was not performed in these subgroups.
a Statistically significant at Po0.05. Trend-like finding at Po0.10.
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Although limited in scope with regard to clinical utility, our findings do not dismiss the possibility that abnormalities in BDNF expression reflect the pathophysiological processes that may underlie depressive illnesses. 1, 3 It should be noted that the associations that we report on, even when adjusting for publication bias, stand out as being strong when compared with other biological abnormalities in depression, for instance blood markers for immune dysregulation (for example, C-reactive protein and interleukin-6; d ¼ 0.15 and 0.25, respectively) or HPA-axis activity (for example, adrenocorticotropin hormone (d ¼ 0.28), for a review on these abnormalities see Penninx et al. 96 ). A difficulty that remains, however, is that we studied peripheral BDNF concentrations. There are indications that BDNF concentrations measured in serum reflect BDNF activity in the brain. 5, 97, 98 However, it has never been proven that peripheral BDNF concentrations directly reflect or influence the pathophysiology of depression. A complication in understanding this is that other tissues than the brain, including immune-, liver-, smooth muscle-and vascular endothelial cells serve as sources of BDNF. 99, 100 The lower peripheral BDNF concentrations in depression and upregulation of this in the course of antidepressant treatment therefore may be an epiphenomenon resulting from an altered BDNF expression (or metabolism) by these peripheral organs. Therefore, the alternations that we rapport on do not necessarily indicate that similar alternations occur at a central level and conclusions with regard to depression related processes in the brain should not be overbearing.
Strengths and limitations
The work presented herein has an obvious strength that it is based on a large amount of data (total N ¼ 9484), yielding in general accurate effect-size estimates. 87 Another strength is that through sensitivity-and moderation analyses, we addressed the potential influence of single studies and sources of heterogeneity. Notwithstanding this, our work carries limitations that need to be reflected upon.
Some limitations regard the methods that we used. First, we relied on funnel plot asymmetry and trim-and-fill estimations to assess publication bias. These methods are limited in that one never knows whether asymmetry in a funnel plot is due to publication bias or to unmeasured differences between studies 86 and whether the most extreme effect-sizes are the ones that are left unpublished. 23 Second, in at least some regards the methods that we used were limited with regard to their ability to detect associations. The meta-regression analyses, for instance, may have been underpowered. Besides, P-values were not adjusted for multiple comparisons. Also methodologically important is that there may have been noise in our assessment of individual study quality. The NOS scale that we used to this end, although recommended by the Cochrane Collaboration, 15 is not rigorously validated and therefore our quality assessments may have been unreliable. 101 Together, this may have limited our ability to detect true associations or may have led to the detection of associations that in reality do not exist. Finally, our findings are limited in scope in that they cannot be directly generalized to other BDNF parameters such as plasma or whole blood BDNF concentrations because there is no one-to-one relationship among these measures. 32, 59, 72 Future work There are several issues that deserve future research attention. First, our finding that a greater increase in serum BDNF concentrations in the course of antidepressant treatment is associated with greater treatment efficacy may fuel work into the temporal dynamics between BDNF expression and treatment efficacy. It would be interesting if future studies could address early changes in the course of (non-)pharmacological treatment, a notion for which some evidence exists. [102] [103] [104] The prediction of how successful a given treatment will be, based on changes in serum BDNF concentrations (that is, a treatment biomarker), is a clinically interesting and relevant topic. 88 In our meta-analysis, we did not have the possibility to address this because most of the included studies reported on pre-and post BDNF concentrations only. Another venue for future investigations regards the distinction between the pro-and the mature BDNF variant. The ELISA kits that currently are in use to quantify BDNF are not sensitive enough to make this distinction. Given the proposed opposing effects of these two BDNF variants (proBDNF is believed to induce apoptosis) 2 it would be interesting to study pro/mature BDNF ratios and whether these differ among diagnostic groups. The tools hereto were only recently developed and validated. 73, 105 With regard to future work on peripheral BDNF concentrations, we finally wish to note that analyses would gain credibility if they were controlled for relevant confounding factors and performed using data (preferably within-subject) on a sufficiently large sample (NB150, according to our power-analyses).
Concluding remarks
Our meta-analyses (aggregating 179 effect-size estimates; N ¼ 9484) initially yielded support for the claim that alternations in serum BDNF concentrations are peripheral manifestations of depression. This is not new. The important contribution of our work is that we clearly show that between-study heterogeneity, underpowered designs and publication bias are at play that give rise to inflated effect-size estimates. Together this suggest that the evidence base for the claim that altered serum BDNF concentrations are peripheral manifestations of depression is slimmer as was initially thought and amidst a lot of noise.
